KR20210005630A - 글루코스-반응성 인슐린 - Google Patents

글루코스-반응성 인슐린 Download PDF

Info

Publication number
KR20210005630A
KR20210005630A KR1020207032777A KR20207032777A KR20210005630A KR 20210005630 A KR20210005630 A KR 20210005630A KR 1020207032777 A KR1020207032777 A KR 1020207032777A KR 20207032777 A KR20207032777 A KR 20207032777A KR 20210005630 A KR20210005630 A KR 20210005630A
Authority
KR
South Korea
Prior art keywords
insulin
peptide
chain
chain peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207032777A
Other languages
English (en)
Korean (ko)
Inventor
대니 훙-치에 츄
Original Assignee
유니버시티 오브 유타 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리서치 파운데이션 filed Critical 유니버시티 오브 유타 리서치 파운데이션
Publication of KR20210005630A publication Critical patent/KR20210005630A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207032777A 2018-04-16 2019-04-15 글루코스-반응성 인슐린 Ceased KR20210005630A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658372P 2018-04-16 2018-04-16
US62/658,372 2018-04-16
PCT/US2019/027484 WO2019204206A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Publications (1)

Publication Number Publication Date
KR20210005630A true KR20210005630A (ko) 2021-01-14

Family

ID=68239869

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032777A Ceased KR20210005630A (ko) 2018-04-16 2019-04-15 글루코스-반응성 인슐린

Country Status (8)

Country Link
US (1) US20210214412A1 (https=)
EP (1) EP3781147A4 (https=)
JP (1) JP2021521230A (https=)
KR (1) KR20210005630A (https=)
CN (1) CN112423741A (https=)
AU (1) AU2019255611A1 (https=)
CA (1) CA3097359A1 (https=)
WO (1) WO2019204206A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
WO2019092125A1 (en) 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
EP3946363A2 (en) * 2019-03-29 2022-02-09 Novo Nordisk A/S Glucose sensitive insulin derivatives
JP7834341B2 (ja) * 2019-07-31 2026-03-24 シーエス ファーマシューティカルズ エルエルシー グルコース調節型立体配座スイッチを有するインスリン類似体
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4126058A1 (en) * 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
CN116096733A (zh) 2020-04-10 2023-05-09 阿卡斯通生物科学公司 Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP2024500284A (ja) * 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
JP2025506650A (ja) * 2022-02-17 2025-03-13 レボロ バイオセラピューティクス リミテッド シャペロニン６０．１由来のペプチドを作製する方法
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体，その製法，及びヒト型インシュリンの製造法
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
EP1453860A2 (en) * 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
CN102770153B (zh) * 2010-02-22 2014-05-07 卡斯西部储备大学 呈可溶和结晶形式的长效胰岛素类似物制剂
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
WO2014093696A2 (en) * 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2016179568A1 (en) * 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins

Also Published As

Publication number Publication date
AU2019255611A1 (en) 2020-11-12
US20210214412A1 (en) 2021-07-15
WO2019204206A1 (en) 2019-10-24
EP3781147A1 (en) 2021-02-24
CA3097359A1 (en) 2019-10-24
EP3781147A4 (en) 2022-04-20
CN112423741A (zh) 2021-02-26
JP2021521230A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
KR20210005630A (ko) 글루코스-반응성 인슐린
Hossain et al. Total chemical synthesis of a nonfibrillating human glycoinsulin
TWI792596B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
EP2694095B1 (en) Compositions comprising glucagon analogs and methods of making and using the same
JP6084215B2 (ja) ポリエチレングリコールまたはその誘導体でｐｅｇ化されたエキセンジン−４類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
EP4159750A1 (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
US8951959B2 (en) Glucagon-like peptide-1 analogues and uses thereof
Kjeldsen et al. Engineering of orally available, ultralong-acting insulin analogues: discovery of OI338 and OI320
TW202039438A (zh) 胰島素接合物
US11041009B2 (en) Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
US11413352B2 (en) Conjugate based systems for controlled insulin delivery
KR20240118786A (ko) Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
EP4545086A1 (en) Incretin analog and use thereof
JP2019536758A (ja) アシル化インスリン化合物
Kabotso et al. Addition of sialic acid to insulin confers superior physical properties and bioequivalence
CN117337299A (zh) 葡萄糖响应性胰岛素类似物葡萄糖传感器的分子设计
CN106554404A (zh) 一种艾塞那肽修饰物及其用途
US20240424109A1 (en) Glucose-responsive insulin conjugates comprising a tetra-valent sugar cluster for treatment of diabetes
Sicinski et al. A robust platform for the molecular design of potent, protease-stable, long-acting GIP analogues
CA2837851A1 (en) Cobalt hexamers of non-peptidyl polymer-insulin conjugates
CN107365375B (zh) 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
CN102203130B (zh) Glp-1衍生物及其应用
US11820805B2 (en) Conjugate based systems for controlled insulin delivery
CA3286784A1 (en) Incretin analog and use thereof
CN119192298A (zh) 一类双位点偶联脂肪酸的BimBH3类似物及其制备方法与应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220408

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240717

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241002

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D